Evercore analyst Gavin Clark-Gartner maintains $Mirum Pharmaceuticals (MIRM.US)$ with a buy rating, and adjusts the target price from $66 to $68.
According to TipRanks data, the analyst has a success rate of 52.5% and a total average return of 25.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Mirum Pharmaceuticals (MIRM.US)$'s main analysts recently are as follows:
Mirum Pharmaceuticals' recent financial disclosure for Q3 surpassed market expectations, primarily driven by robust Livmarli sales. Although certain reimbursement factors may have advanced some of this revenue, the continued upward trajectory of Livmarli's launch is promising, contributing increasingly to the overall franchise sales.
Mirum Pharmaceuticals recorded a substantial performance that surpassed expectations, primarily fueled by the success of Livmarli. This has resulted in an upward revision of their financial guidance for FY2024, exceeding the initial high-end projections.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
Evercore分析師Gavin Clark-Gartner維持$Mirum Pharmaceuticals (MIRM.US)$買入評級,並將目標價從66美元上調至68美元。
根據TipRanks數據顯示,該分析師近一年總勝率為52.5%,總平均回報率為25.5%。
此外,綜合報道,$Mirum Pharmaceuticals (MIRM.US)$近期主要分析師觀點如下:
Mirum Pharmaceuticals最近的第三季度財務披露超出了市場預期,這主要是由Livmarli的強勁銷售推動的。儘管某些報銷因素可能增加了部分收入,但Livmarli推出的持續上升勢頭令人鼓舞,對整個特許經營銷售的貢獻越來越大。
Mirum Pharmicals的強勁業績超出了預期,這主要是由Livmarli的成功推動的。這導致他們對 FY2024 的財務指導向上修正,超過了最初的高端預期。
提示:
TipRanks為獨立第三方,提供金融分析師的分析數據,並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議,僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級,分析師星級代表分析師所有推薦的過往表現,通過分析師的總勝率和平均回報率综合計算得出,星星越多,則該分析師過往表現越優異,最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否,取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合,並根據評級變化對組合進行調整,在近一年中該投資組合所獲得的回報率。